These inhibitors have shown efficacy in vitro against glioblastoma with PTPRZ1-MET rearrangement; however, their clinical efficacy in glioblastoma is currently unclear, with ongoing clinical trials investigating their potential. The gene discussed is MET; the disease is glioblastoma.